Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 38.7849
- Book/Share 32.6431
- PB 7.1828
- Debt/Equity 0.5777
- CurrentRatio 1.0736
- ROIC 0.142
- MktCap 564907422566.0
- FreeCF/Share 7.8498
- PFCF 29.6322
- PE 21.2444
- Debt/Assets 0.2375
- DivYield 0.0219
- ROE 0.3488
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Morgan Stanley | Equal Weight | Overweight | -- | $262 | Jan. 28, 2026 |
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ is banking on Darzalex, Tremfya and new drugs to offset Stelara's LOE and Part D headwinds in Q2 Innovative Medicine sales.
Read More
Johnson & Johnson: Patience Will Be Rewarded
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson faces legal pressures from talc lawsuits, which is likely to create persisting growth and valuation headwinds. The latest dividend increase of 4.8% signals continued profit growth, though below JNJ's historical average. However, I believe the market has also priced in these issues already.
Read More
J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ's MedTech sales face pressure from China and competition but new products may lead to a stronger second half of 2025.
Read More
Johnson & Johnson: Undervalued Dividend King With 65% Upside Potential
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson is a stable, dividend-growth powerhouse with 62 years of increases and a 3.44% forward yield, ideal for conservative, long-term investors. Despite recent legal headwinds and flat core growth, JNJ remains undervalued, trading at a significant discount to the sector median P/E. Talc litigation overhang has depressed sentiment, but 95% of cases are resolved and market recovery suggests the worst is priced in.
Read More
How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Income Accelerator Portfolio balances income, growth, and capital appreciation, now enhanced by the global diversification from Allianz and LVMH. We focus on financially healthy companies with sustainable dividends and strong competitive advantages, optimizing risk-reward through sector and geographic diversification. The portfolio's Weighted Average Dividend Yield [FWD] of 4.05% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.06% project a Yield on Cost above 11% in 15 years.
Read More
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Negative
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
Read More
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.
Read More
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa. , June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ …
Read More
If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global Diversification
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
I added Allianz and LVMH to The Dividend Income Accelerator Portfolio for their blend of dividend yield, growth, and financial strength. Both companies offer strong dividend growth potential—Allianz with a Dividend Yield [FWD] of 4.31%, and LVMH with a Dividend Yield [FWD] of 3.19%—plus robust long-term growth prospects. These additions improve our portfolio's potential risk-adjusted returns, valuation, and global diversification, aligning with our strategy of balancing income and growth.
Read More
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
Published: June 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Allocating 10% to 20% to dividend stocks balances growth-heavy portfolios, leveraging compounding returns to navigate geopolitical and monetary challenges.
Read More
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
Published: June 17, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but big pharma provides the infrastructure and market access.
Read More
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Read More
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Published: June 13, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose MILAN , June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell …
Read More
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Published: June 12, 2025 by: PRNewsWire
Sentiment: Neutral
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation MILAN , June 12, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The …
Read More
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Read More
3 Top Dividend Stocks Analysts Are Bullish on Right Now
Published: June 06, 2025 by: MarketBeat
Sentiment: Positive
We're at the end of earnings season. That means it's time for analysts to weigh in on the outlook for specific stocks.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.
Read More
3 Fortress Dividend Stocks Set to Thrive, Even if the Economy Slumps
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks have solid underlying businesses. The cash flows should remain consistent regardless of the broader economic environment.
Read More
Top 3 dividend stocks to buy for 2026
Published: June 04, 2025 by: Finbold
Sentiment: Positive
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Read More
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent.
Read More
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
Read More
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These …
Read More
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO ® in transplant-ineligible newly diagnosed patients CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from two studies highlighting that a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly …
Read More
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 50 percent reduction in disease progression in BRCA-altered mCSPC vs. current standard of care CHICAGO , June 3, 2025 /PRNewswire/ -- Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) genetic alterations including BRCA.
Read More
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
Published: June 02, 2025 by: Schwab Network
Sentiment: Positive
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Read More
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100